Sign in Subscribe
Cancer research

Novel ER-Targeted PEGylated Liposomes Exhibit Enhanced Therapeutic Efficacy Against Ovarian Cancer

Strategic Insights

— 1 min read

Researchers at Jilin University have developed a novel ER-targeted PEGylated liposome (ES-SSL-PTX/CDDP) coencapsulating paclitaxel (PTX) and cisplatin (CDDP) to enhance therapeutic efficacy and mitigate systemic toxicity in the treatment of ovarian cancer. The research demonstrates the potential of this targeted delivery system to improve the efficacy and reduce the toxicity of platinum-taxane regimens in ovarian cancer treatment. The study highlights the effectiveness of ES-SSL-PTX/CDDP in promoting sustained release, encapsulation efficiencies, and reduced side effects.

Key Takeaways:

  • The ER-targeted PEGylated liposome (ES-SSL-PTX/CDDP) demonstrated a sustained release pattern with release rates of 50.5% at 12 hours and 70.3% at 24 hours.
  • The encapsulation efficiencies for PTX and CDDP were 83.7% and 41.1%, respectively, indicating high loading capacity of the liposomes.
  • The hydrodynamic diameter of ES-SSL-PTX/CDDP was around 150 nm, and the zeta potential was about -20 mV, suggesting optimal size and charge for targeted delivery.
  • The study concluded that ES-SSL-PTX/CDDP could improve the efficacy and reduce the toxicity of platinum-taxane regimens in the treatment of ovarian cancer.
  • Additional authors on the research include Ming Zhu, Huan Tang, Yizhuo Xie, Zhe Lv, Han Bao, Yan Zhang, Dongfanghui Miao, Xin Guo, Kejia Chen, Shanshan Wang, Liangping Yu, and Jin Pei.
  • The research has been peer-reviewed and published in the journal Molecular Pharmaceutics.

Statistics:

  • The spherical shape of ES-SSL-PTX/CDDP was maintained even after 24 hours, indicating stability and consistency.
  • The release rate of PTX from ES-SSL-PTX/CDDP was significantly higher than that of free PTX, suggesting enhanced therapeutic efficacy.
  • The encapsulation efficiency of CDDP was lower compared to PTX, but still within the acceptable range.
  • The study used a total of 120 female BALB/c nude mice to evaluate the therapeutic efficacy of ES-SSL-PTX/CDDP.

Sources:

  • Jilin University, Dept. of Biopharmacy, School of Pharmaceutical Sciences, Changchun, People's Republic of China.
  • American Chemical Society (ACS) - www.acs.org
  • Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp
  • NewsRx LLC - NewsRx. Jilin University Reports Findings in Cancer Gene Therapy (Antitumor Efficacy, Pharmacokinetics, and Toxicity Studies of Novel Estrogen Receptors Targeted PEGylated Liposomes Encapsulating Paclitaxel and Cisplatin in SKOV-3 Tumor-Bearing Nude ...). Chemicals & Chemistry. June 13, 2025; p 1830.

Read more